TWI835848B - 經改造t細胞之條件活性嵌合抗原受體 - Google Patents

經改造t細胞之條件活性嵌合抗原受體 Download PDF

Info

Publication number
TWI835848B
TWI835848B TW108132177A TW108132177A TWI835848B TW I835848 B TWI835848 B TW I835848B TW 108132177 A TW108132177 A TW 108132177A TW 108132177 A TW108132177 A TW 108132177A TW I835848 B TWI835848 B TW I835848B
Authority
TW
Taiwan
Prior art keywords
cells
antigen
antibodies
antibody
protein
Prior art date
Application number
TW108132177A
Other languages
English (en)
Chinese (zh)
Other versions
TW202024124A (zh
Inventor
杰 Ｍ 休特
Original Assignee
美商拜奧亞特拉公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/125,302 external-priority patent/US11111288B2/en
Application filed by 美商拜奧亞特拉公司 filed Critical 美商拜奧亞特拉公司
Publication of TW202024124A publication Critical patent/TW202024124A/zh
Application granted granted Critical
Publication of TWI835848B publication Critical patent/TWI835848B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4212—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4251—Kinases, e.g. Raf or Src
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW108132177A 2018-09-07 2019-09-06 經改造t細胞之條件活性嵌合抗原受體 TWI835848B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/125,302 US11111288B2 (en) 2014-08-28 2018-09-07 Conditionally active chimeric antigen receptors for modified t-cells
US16/125,302 2018-09-07

Publications (2)

Publication Number Publication Date
TW202024124A TW202024124A (zh) 2020-07-01
TWI835848B true TWI835848B (zh) 2024-03-21

Family

ID=69721682

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108132177A TWI835848B (zh) 2018-09-07 2019-09-06 經改造t細胞之條件活性嵌合抗原受體

Country Status (6)

Country Link
EP (1) EP3847191A4 (fr)
JP (1) JP7432250B2 (fr)
CN (1) CN112823166B (fr)
AU (1) AU2019334864B2 (fr)
TW (1) TWI835848B (fr)
WO (1) WO2020050993A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230203168A1 (en) * 2020-06-02 2023-06-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Dual EGFR-MUC1 Chimeric Antigen Receptor T Cells
WO2022187182A1 (fr) * 2021-03-02 2022-09-09 The Trustees Of The University Of Pennsylvania Ciblage de lymphocytes t régulateurs vers des cellules d'îlots pour freiner ou inverser le diabète de type 1
CN115368470A (zh) * 2021-05-21 2022-11-22 南京卡提医学科技有限公司 靶向b7-h3的嵌合受体及其用途
CN115477704B (zh) * 2021-06-16 2024-02-23 四川大学华西医院 一种基于lox1构建的嵌合抗原受体免疫细胞制备及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130280220A1 (en) * 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
WO2014127261A1 (fr) * 2013-02-15 2014-08-21 The Regents Of The University Of California Récepteur d'antigène chimère et procédés d'utilisation de celui-ci
CN107074975A (zh) * 2014-08-28 2017-08-18 生物蛋白有限公司 用于修饰的t细胞的条件活性嵌合抗原受体
US20170247685A1 (en) * 2014-09-03 2017-08-31 Bioatla, Llc Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2331566B1 (fr) * 2008-08-26 2015-10-07 City of Hope Procédé et compositions pour fonctionnement amélioré d'effecteur antitumoral de lymphocytes t
US11111288B2 (en) * 2014-08-28 2021-09-07 Bioatla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
SMT202600033T1 (it) 2016-04-15 2026-03-09 Bioatla Inc Anticorpi anti-axl, frammenti di anticorpo e loro immunoconiugati e loro utilizzi
AU2017320874B2 (en) 2016-08-31 2024-03-07 Bioatla, Llc Conditionally active polypeptides and methods of generating them
JP7280827B2 (ja) * 2017-01-18 2023-05-24 エクスマ バイオテック コーポレイション Ａｘｌまたはｒｏｒ２に対するキメラ抗原受容体およびその使用方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130280220A1 (en) * 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
WO2014127261A1 (fr) * 2013-02-15 2014-08-21 The Regents Of The University Of California Récepteur d'antigène chimère et procédés d'utilisation de celui-ci
CN107074975A (zh) * 2014-08-28 2017-08-18 生物蛋白有限公司 用于修饰的t细胞的条件活性嵌合抗原受体
US20170247685A1 (en) * 2014-09-03 2017-08-31 Bioatla, Llc Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts

Also Published As

Publication number Publication date
JP2021536256A (ja) 2021-12-27
AU2019334864A1 (en) 2021-03-11
TW202024124A (zh) 2020-07-01
AU2019334864B2 (en) 2025-11-20
WO2020050993A3 (fr) 2020-04-16
CN112823166B (zh) 2025-01-24
WO2020050993A2 (fr) 2020-03-12
EP3847191A4 (fr) 2022-06-08
JP7432250B2 (ja) 2024-02-16
EP3847191A2 (fr) 2021-07-14
CN112823166A (zh) 2021-05-18

Similar Documents

Publication Publication Date Title
JP7405444B2 (ja) 修飾ｔ細胞に対する条件的活性型キメラ抗原受容体
JP2021137013A5 (fr)
US11111288B2 (en) Conditionally active chimeric antigen receptors for modified t-cells
TWI835848B (zh) 經改造t細胞之條件活性嵌合抗原受體
HK40082297A (en) Conditionally active chimeric antigen receptors for modified t-cells
HK1235798B (en) Conditionally active chimeric antigen receptors for modified t-cells